Correction to: International Journal of Impotence Research
In the published article the following incorrect statement appeared in the Patients and methods section:
Group 1 (n = 75); was given on demand lidocaine 5% spray for 8 weeks (One to two applications (1–2 ml) of lidocaine 5% sprays; contain 5–10 mg of lidocaine, in a metered-dose aerosol-delivery system) (Lidocaine topical aerosol U.S.P. 38, The Arab Drug Co, Cairo, Egypt). Group 2 (n = 75); was given placebo in the form on demand alcohol spray for 8 weeks (One to two applications (1–2 ml) of alcohol 40% sprays).
The statement should read as follows:
Group 1 (n = 75); was given on demand lidocaine 5% spray for 8 weeks (One to two applications (0.1–0.2 ml) of lidocaine 5% sprays; contain 5–10 mg of lidocaine, in a metered-dose aerosol-delivery system) (Lidocaine topical aerosol U.S.P. 38, The Arab Drug Co, Cairo, Egypt). Group 2 (n = 75); was given placebo in the form on demand alcohol spray for 8 weeks (One to two applications (0.1–0.2 ml) of alcohol 40% sprays).
This has been corrected in both the PDF and HTML versions of the Article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
El-Hamd, M.A. Correction to: Effectiveness and tolerability of lidocaine 5% spray in the treatment of lifelong premature ejaculation patients: a randomized single-blind placebo-controlled clinical trial. Int J Impot Res 32, 367 (2020). https://doi.org/10.1038/s41443-020-0229-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41443-020-0229-5
